News stories about Checkpoint Therapeutics (NASDAQ:CKPT) have been trending somewhat positive this week, Accern reports. The research firm rates the sentiment of press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Checkpoint Therapeutics earned a news sentiment score of 0.02 on Accern’s scale. Accern also gave news coverage about the company an impact score of 44.8707019549081 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Shares of Checkpoint Therapeutics (NASDAQ:CKPT) opened at $3.58 on Monday. Checkpoint Therapeutics has a 1 year low of $3.35 and a 1 year high of $15.00. The firm has a market cap of $92.09 and a P/E ratio of -3.20.
CKPT has been the subject of a number of analyst reports. HC Wainwright initiated coverage on shares of Checkpoint Therapeutics in a research report on Friday, December 8th. They issued a “buy” rating and a $11.00 price target for the company. Zacks Investment Research upgraded shares of Checkpoint Therapeutics from a “hold” rating to a “buy” rating and set a $4.75 price target for the company in a research report on Thursday, November 23rd.
ILLEGAL ACTIVITY NOTICE: “Checkpoint Therapeutics (CKPT) Getting Somewhat Positive Media Coverage, Report Shows” was first posted by Community Financial News and is owned by of Community Financial News. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.com-unik.info/2017/12/25/checkpoint-therapeutics-ckpt-getting-somewhat-positive-media-coverage-report-shows.html.
Checkpoint Therapeutics, Inc is an immuno-oncology biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. The Company is engaged in developing a portfolio of human immuno-oncology targeted antibodies.
Receive News & Ratings for Checkpoint Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Checkpoint Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.